NFE2L2 and hepatocellular carcinoma: By inhibiting ferroptosis in HCC, blocking the activity of the N6-methyladenosine reader insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) renders NRF2 mRNA unstable and thus circumvents sorafenib resistance (235).